Share on StockTwits

Research analysts at Bank of America assumed coverage on shares of Theravance Biopharma (NASDAQ:TBPH) in a report released on Friday. The firm set a “buy” rating and a $34.00 price target on the stock. Bank of America’s target price suggests a potential upside of 74.36% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Robert W. Baird initiated coverage on shares of Theravance Biopharma in a research note on Monday, June 2nd. They set a “neutral” rating on the stock.

Shares of Theravance Biopharma (NASDAQ:TBPH) traded up 1.40% during mid-day trading on Friday, hitting $34.87. The stock had a trading volume of 401,742 shares. Theravance Biopharma has a 1-year low of $14.75 and a 1-year high of $35.24. The stock has a 50-day moving average of $25.79 and a 200-day moving average of $25.79.

Theravance Biopharma, Inc, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (NASDAQ:TBPH)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.